I-Mab Plans Hong Kong IPO and Rebranding to NovaBridge Biosciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 16 2025
0mins
Should l Buy ?
New Business Model: I-Mab is shifting its focus to a new business model aimed at enhancing global capabilities for faster access to medicines and strategic growth.
IPO Plans: The company plans to pursue a dual listing on the Nasdaq and Hong Kong Stock Exchange, rebranding itself as NovaBridge Biosciences.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
